dacarbazine medec 200 mg, powder for solution for injection / infusion
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - dacarbazine - powder for solution for injection/infusion - dacarbazine 10 mg/ml - antineoplastic agents
dacarbazine medac 100 milligram pdr for soln inj/inf
medac gesellschaft fur klinische spezialpraparate - dacarbazine citrate - pdr for soln inj/inf - 100 milligram
dacarbazine medac
medac gmbh - dacarbazine - powder lyophilized for solution for injection - 100mg
dacarbazine 1g powder for solution for infusion vials
medac uk - dacarbazine citrate - powder for solution for infusion - 1gram
dacarbazine 100mg powder for solution for injection vials
medac uk - dacarbazine citrate - powder for solution for injection - 100mg
dacarbazine 500mg powder for solution for infusion vials
medac uk - dacarbazine citrate - powder for solution for infusion - 500mg
dacarbazine 200mg powder for solution for injection vials
medac uk - dacarbazine citrate - powder for solution for injection - 200mg
dacarbazine sandoz
sandoz pty ltd - dacarbazine -
hospira dacarbazine for injection usp, 200 mg vial
hospira australia pty ltd - dacarbazine, quantity: 200 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; citric acid; sodium hydroxide - dacarbazine for injection is indicated in the treatment of metastic malignant melanoma. in addition, its also indicated for hodgkin's disease as a second line therapy when used in combination with other effective agents.
hospira dacarbazine for injection 600 mg/ vial
hospira australia pty ltd - dacarbazine, quantity: 600 mg - injection, powder for - excipient ingredients: citric acid monohydrate; mannitol; sodium hydroxide - dacarbazine is indicated for the treatment of patients with metastatic malignant melanoma. dacarbazine is used as part of combination chemotherapy for the treatment of advanced hodgkin's disease, advanced adult soft tissue sarcomas (except mesothelioma and kaposi sarcoma). dacarbazine has been shown, when used in combination with other cytotoxic agents, to be of use in the treatment of other malignant diseases including carcinoma of the colon, ovary, breast, lung, testicular teratoma, and solid tumours in children.